GLAXO SUING GENEVA FOR ZANTAC FORM I ANDA FILING
Executive Summary
GLAXO SUING GENEVA FOR ZANTAC FORM I ANDA FILING, citing patent infringement, Glaxo announced April 28. The suit, filed the same day in Newark federal court, alleges infringement of Glaxo's product and process patents for Form 2 ranitidine HCl, the active ingredient in Zantac.